Medical Devices APAC

APAC Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $690.1 Mn Placeholder estimate
Estimate 2025 $815.0 Mn 22.9% of the global market
Projected 2034 $3.64 Bn 346.9% Adds $2.83 Bn over 9 forecast years
CAGR 2025–2034 18.1% Faster than 91% of 173 Medical Devices markets here
Key players 6 +1
  • APAC is 22.9% of the global market.
  • Among regions, the largest is North America at $2.00 Bn.
  • Fastest growing: Africa at 18.2% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.83 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $690.1 Mn — —
2025 (base) $815.0 Mn +$124.9 Mn —
2026 (forecast) $962.5 Mn +$147.5 Mn +18.1%
2027 (forecast) $1.14 Bn +$174.2 Mn +39.5%
2028 (forecast) $1.34 Bn +$205.7 Mn +64.7%
2029 (forecast) $1.59 Bn +$243.0 Mn +94.5%
2030 (forecast) $1.87 Bn +$287.0 Mn +129.7%
2031 (forecast) $2.21 Bn +$338.9 Mn +171.3%
2032 (forecast) $2.61 Bn +$400.2 Mn +220.4%
2033 (forecast) $3.08 Bn +$472.7 Mn +278.4%
2034 (forecast) $3.64 Bn +$558.2 Mn +346.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$815.0 Mn placeholder estimate
Forecast, 2034$3.64 Bn placeholder estimate
Growth (CAGR), 2025–203418.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Active clinical trials93 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: Asia Pacific Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $690.1 Mn in 2024, $815.0 Mn in 2025 and $3.64 Bn in 2034, 18.1% CAGR.
Asia Pacific Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in APAC

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in APAC

Automated Insulin Delivery Systems in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 93 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Clinical trials

93 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Sanofi 9 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 9 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novo Nordisk A/S 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Insulet Corporation 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Medtronic 5 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Afghanistan25.32022
Australia8.12022
Bangladesh17.92022
China11.22022
India22.62022
Indonesia12.82022
Japan6.42022
Malaysia26.72022
Myanmar13.82022
Nepal15.82022
New Zealand9.02022
Pakistan30.92022
Philippines13.22022
Singapore13.12022
Thailand12.32022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in Asia Pacific?
Placeholder estimate: about $815.0 Mn in 2025, rising to about $3.64 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in Asia Pacific growing?
Placeholder estimate: about 18.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
How many clinical trials on Automated Insulin Delivery Systems are running in Asia Pacific?
93 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Automated Insulin Delivery Systems?
PubMed lists 373 papers on Automated Insulin Delivery Systems added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diabetes and remote monitoring and wearables

See the topic